INTRODUCTION
============

Lung function starts to decline in the third decade of life ([@b1]), but with different rates of decline across individuals ([@b2]). Lower lung function is a strong predictor of mortality ([@b3], [@b4]), and faster lung function decline has been associated with increased risks of hospitalizations related to chronic obstructive pulmonary disease ([@b5]), a leading cause of mortality in all countries ([@b6]). There are multiple sources of the heterogeneity in lung function decline in adults, and the available evidence from population-based studies suggests that a diet rich in antioxidants is positively related to lung function and slower age-related decline in lung function ([@b7]). For vitamin C, β-carotene, and fiber, prospective and cross-sectional studies show that individuals with high intakes had better lung function than those with low intakes ([@b8]--[@b13]), whereas less consistent findings are observed for other antioxidants, including vitamin E ([@b10], [@b11], [@b14], [@b15]).

Growing evidence supports the hypothesis that dietary flavonoids may also have a beneficial effect on lung function. Experimental studies in animals have found specific flavonoids to attenuate airway hyperresponsiveness, inflammation, and remodeling ([@b16]--[@b19]). Cross-sectional findings from 2 population-based studies in adults also observed positive associations between dietary flavan-3-ol and flavonol intake with forced expiratory volume in 1 s (FEV~1~)[^10^](#fn4){ref-type="fn"} and with forced vital capacity (FVC), respectively ([@b20], [@b21]). To our knowledge, no longitudinal studies to date have evaluated if specific flavonoid subclasses are associated with slower rates of age-related lung function decline.

In addition, no studies to our knowledge have examined the impact of dietary anthocyanin intake on lung function. Anthocyanins are a subclass of flavonoids derived from fruit, predominantly berries, which have been shown to be associated with lower risk of hypertension and myocardial infarction ([@b22], [@b23]) and with lower levels of inflammation ([@b24]). Findings from acute and short-term clinical trials also suggest beneficial effects of both purified anthocyanins and intake of berries on a range of inflammatory biomarkers ([@b25]--[@b27]). The ingestion of anthocyanin-rich strawberries and fruit juice has also been shown to improve antioxidant enzyme activities and plasma antioxidant capacity in experimental human studies, providing evidence of beneficial effects on oxidative stress, another key mechanism involved in lung function ([@b28], [@b29]).

Given the previous findings observed for flavonoid intake with lung function ([@b20], [@b21]), and for flavonoid intake with inflammation and oxidative stress biomarkers ([@b24], [@b28], [@b29]), we hypothesized that a higher habitual intake of anthocyanins, flavonols, flavan-3-ols, and their polymeric forms would be associated with beneficial changes in lung function. We investigated if dietary intake of the major flavonoid subclasses was associated with a slower age-related decline in lung function in a community-based cohort of elderly men living in the Boston area.

METHODS
=======

Study participants included in this longitudinal analysis were enrolled in the VA (Veterans Affairs) Normative Aging Study, an ongoing longitudinal study of aging established in 1963, details of which have been published previously ([@b30]). Briefly, the Normative Aging Study is a closed cohort of 2280 male volunteers from the Greater Boston area aged 21--80 y at entry, who enrolled after an initial health screening determined that they were free of known chronic medical conditions. Participants have undergone detailed examinations every 3--5 y, including routine physical examinations, laboratory tests, collection of medical history information, and completion of questionnaires on smoking history, food intake, and other factors that may influence health, which were confirmed by a trained interviewer. Physical examinations included measurement of height and lung function (FEV~1~ and FVC). Pulmonary disorders confirmed by a physician (asthma, chronic bronchitis, or emphysema) and smoking history were collected through the American Thoracic Society questionnaire ([@b31]). The present study was approved by the human research committees of the Harvard School of Public Health and the Veterans Affairs Boston Health care System, and written informed consent was obtained from subjects before participation.

For the present analysis, there were 1281 eligible participants with at least 1 visit between May 1992 and October 2008, when computations of dietary flavonoid intake were available for all self-administered semi-quantitative food-frequency questionnaires (FFQs). Of those eligible, there were 1048 participants with at least 1 visit with data available on spirometry, dietary flavonoid intake, and covariates of interest (**Supplemental Figure 1**). This analysis included 839 participants whose lung function was measured and who completed an FFQ in at least 2 visits (*n* = 2623 visits); there were 287 participants with 2 visits, 262 with 3 visits, 187 with 4 visits, and 103 with 5 visits. Visits with implausible values for total energy intake for men (\<800 or \>4200 kcal) were excluded from the analysis. For additional description of the study participation, please refer to the Methods section of the **Supplemental Material**.

Outcome assessment
------------------

Pulmonary function tests were performed as previously reported ([@b32]), and acceptability of spirograms was judged according to American Thoracic Society standards. Briefly, a water-filled recording spirometer was used to obtain measures of FEV~1~ (mL) and FVC (mL), with values adjusted by body temperature and ambient pressure. These spirometric tests were performed in accordance with American Thoracic Society guidelines ([@b33], [@b34]). In this study, approximate normal distributions were observed for both FEV~1~ and FVC.

Dietary assessment
------------------

Since May of 1992, the average daily dietary intakes of food and beverage items were assessed with a self-administered, validated, semi-quantitative FFQ adapted from the questionnaire used in the Nurses' Health Study. Details on the reproducibility and validity of this FFQ for estimating daily nutrient intakes were published elsewhere ([@b35], [@b36]). A database for assessment of intake of the different flavonoid subclasses was constructed as previously described ([@b22]) and was based on the updated and expanded USDA flavonoid content of foods and the proanthocyanidin databases ([@b37], [@b38]) together with other sources. Intakes of individual compounds were calculated as the sum of the consumption frequency of each food multiplied by the content of the specific flavonoid for the specified portion size. We derived intakes (mg/d) of the subclasses commonly consumed in the US diet, specifically anthocyanins (cyanidin, delphinidin, malvidin, pelargonidin, petunidin, peonidin), flavanones (eriodictyol, hesperetin, naringenin), flavan-3-ols (catechins, gallocatechins, epicatechin, epigallocatechin, epicatechin-3-gallate, epigallocatechin-3-gallate), flavonols (quercetin, kaempferol, myricetin, isohamnetin), flavones (luteolin, apigenin), and polymers (including proanthocyanidins excluding monomers, theaflavins, and thearubigins). Refer to the Supplemental Material for additional details describing the FFQ and computation of flavonoid subclasses.

Statistical analysis
--------------------

All statistical analyses were carried out by using SAS version 9.3 (SAS Institute). Utilizing concurrent measures of lung function, flavonoid intake, and covariates, we used time-varying linear mixed-effects regression models with random participant-specific intercepts, which account for the correlation of repeated measures ([@b39]), to model continuous FEV~1~ and FVC as a function of major subclass of flavonoid intake. Each flavonoid subclass was characterized in quartiles (lowest quartile as reference) and was fit in a separate model and adjusted for age at first visit, height (cm), total energy intake (kcal/d, in quartiles), and time since first visit; we estimated the adjusted difference in annual change in lung function over time associated with flavonoid intake via an interaction between each flavonoid quartile (lowest quartile as reference) and time since first visit in the model.

All of the models were further adjusted for nondietary and dietary factors that were ascertained at each visit, including the following: race (black or white as reference), smoking status (current smoker, recent quitter, longtime quitter, or never smoker as reference), cumulative pack-years smoked, physician diagnosis of chronic bronchitis or asthma or emphysema (no as reference), use of medication for asthma (no as reference), use of statins (no as reference), years of education (\<12, 12, 13--15, \>15 y as reference), percentage of census tract below poverty level, total fruit intake (servings/d, in quartiles), total vegetable intake (servings/d, in quartiles), and physical activity (metabolic equivalent tasks/wk, in quartiles). We evaluated effect modification by smoking status (ever or never), physician-diagnosed obstructive lung disease (asthma, chronic bronchitis, or emphysema), and obesity \[BMI (in kg/m^2^) ≥30 or \<30\]. Three-way interaction terms between flavonoid subclass intake, time since first visit, and the modifying variables were tested separately to evaluate whether the potential effect modifiers underlie susceptibility to the exposure response.

In addition, we adjusted for the intake of hot or cold cereal (servings/d), dark fish (servings/wk), processed meats (servings/d), caffeine (mg/d), vitamin C (without supplements, mg/d), omega-3 fatty acids (g/d), total dietary fiber intake (g/d), and for the presence of comorbid conditions including hypertension, coronary heart disease, and diabetes mellitus. We also conducted food-based analyses of the main sources of each flavonoid subclass for all FFQs collected between 1992 and 2004 (*n* = 3366). Because healthier men may be more likely to participate in a subsequent follow-up visits, we also applied stabilized inverse probability weights to correct for this potential survival bias ([@b40]) in all models. Refer to the Supplemental Material for additional description of the computation of stabilized inverse probability weights.

RESULTS
=======

Characteristics of the participants by yearly average anthocyanin intake measured at first visit are presented in [**Table 1**](#tbl1){ref-type="table"}. The median age of all of the participants at the first visit was 66.8 y, with an age range of 49--92 y. Participants with higher anthocyanin intakes smoked less, were more physically active, and consumed more fruit and vegetables. The mean follow-up time for all participants was 7.4 y, and the maximum follow-up time was 16 y. The distributions of FEV~1~ and FVC levels among all participants at each visit are summarized in **Supplemental Table 1**.

###### 

Characteristics of participants at first visit by quartiles of total anthocyanin intake[^1^](#tblfn1){ref-type="table-fn"}

                                                                        Anthocyanin intake \[median (IQR)\]                                                   
  --------------------------------------------------------------------- --------------------------------------------------- ---------------- ---------------- ----------------
  Participants, *n*                                                     211                                                 208              210              210
  FEV~1~, mL                                                            2747.4 ± 668.6[^2^](#tblfn2){ref-type="table-fn"}   2789.2 ± 630.4   2838.1 ± 628.1   2893.4 ± 634.6
  FVC, mL                                                               3681.8 ± 764.9                                      3760.3 ± 735.5   3787.5 ± 742.1   3850.8 ± 754.7
  Age, y                                                                65.8 ± 7.1                                          67.6 ± 7.0       67.1 ± 6.5       66.8 ± 6.7
  Height, cm                                                            1730.7 ± 68.9                                       1736.0 ± 71.9    1737.2 ± 64.3    1743.0 ± 65.6
  Smoking status, *n* (%)                                                                                                                                     
   Current smokers                                                      20 (9.5)                                            14 (6.7)         7 (3.3)          6 (2.9)
   Recent quitters (\<10 y)                                             30 (14.2)                                           27 (13.0)        21 (10.0)        20 (9.5)
   Longtime quitters (≥10 y)                                            107 (50.7)                                          104 (50.0)       122 (58.1)       117 (55.7)
   Never smokers                                                        54 (25.6)                                           63 (30.3)        60 (28.6)        67 (31.9)
  Cumulative pack-years                                                 27.0 ± 29.2                                         19.6 ± 22.4      20.9 ± 28.2      16.2 ± 22.1
  Race, *n* (%)                                                                                                                                               
   Black                                                                1 (0.5)                                             6 (2.9)          5 (2.4)          1 (0.5)
   White                                                                210 (99.5)                                          202 (97.1)       205 (97.6)       209 (99.5)
  Years of education                                                    14.1 ± 2.9                                          14.5 ± 2.8       15.4 ± 2.8       15.5 ± 2.9
  Percentage below poverty level in census tract                        6.4 ± 5.5                                           6.8 (5.9)        5.8 (5.1)        5.7 (4.7)
  Physician-diagnosed asthma, *n* (%)                                   14 (6.6)                                            9 (4.3)          12 (5.7)         6 (2.9)
  Physician-diagnosed chronic bronchitis, *n* (%)                       14 (6.6)                                            12 (5.8)         16 (7.6)         10 (4.8)
  Physician-diagnosed emphysema, *n* (%)                                8 (3.8)                                             11 (5.3)         14 (6.7)         8 (3.8)
  Use of asthma medications, *n* (%)                                    6 (2.8)                                             13 (6.3)         7 (3.3)          5 (2.4)
  Use of statins, *n* (%)                                               29 (13.7)                                           29 (13.9)        29 (13.8)        29 (13.8)
  Metabolic equivalent tasks/wk                                         11.4 ± 13.4                                         18.5 ± 24.7      20.2 ± 25.4      22.2 ± 27.6
  Total energy intake, kcal/d                                           1678.3 ± 568.7                                      2005.7 ± 592.0   2060.3 ± 567.9   2249.1 ± 651.4
  Total fruit intake, servings/d                                        1.7 ± 1.2                                           2.6 ± 1.5        2.7 ± 1.5        3.6 ± 2.1
  Total vegetable intake, servings/d                                    2.4 ± 1.6                                           3.2 ± 1.7        3.5 ± 1.9        4.3 ± 2.3
  Total dietary fiber intake,[^3^](#tblfn3){ref-type="table-fn"} mg/d   15.5 ± 6.2                                          20.6 ± 6.5       22.4 ± 8.7       25.4 ± 9.0
  Hot and cold cereal intake, servings/d                                0.4 ± 0.4                                           0.5 ± 0.4        0.5 ± 0.4        0.6 ± 0.6
  Vitamin C intake (without supplements), mg/d                          121.6 ± 70.0                                        169.1 ± 88.6     169.4 ± 70.8     209.9 ± 115.1
  Caffeine intake, mg/d                                                 249.3 ± 191.2                                       250.7 ± 194.5    231.8 ± 186.5    207.1 ± 178.6
  n--3 Intake,[^4^](#tblfn4){ref-type="table-fn"} g/d                   0.3 ± 0.3                                           0.3 ± 0.3        0.3 ± 0.2        0.4 ± 0.4
  Dark fish intake, servings/d                                          0.0 ± 0.1                                           0.1 ± 0.1        0.1 ± 0.1        0.1 ± 0.1
  Other fish intake, servings/d                                         0.1 ± 0.1                                           0.1 ± 0.2        0.1 ± 0.1        0.1 ± 0.1
  Cold cuts, servings/d                                                 0.2 ± 0.4                                           0.2 ± 0.2        0.2 ± 0.4        0.1 ± 0.2
  Flavanones, mg/d                                                      44.8 ± 45.0                                         59.3 ± 46.3      56.8 ± 39.9      65.2 ± 43.9
  Flavan-3-ols, mg/d                                                    45.2 ± 59.1                                         52.7 ± 60.1      51.7 ± 58.5      60.3 ± 61.7
  Flavonols, mg/d                                                       14.8 ± 10.0                                         18.6 ± 10.9      19.4 ± 10.9      24.7 ± 12.3
  Flavones, mg/d                                                        1.8 ± 1.5                                           2.5 ± 1.5        2.6 ± 1.3        3.4 ± 1.8
  Polymers, mg/d                                                        154.3 ± 193.9                                       207.0 ± 204.8    213.5 ± 207.0    267.0 ± 207.3
  Hypertension, *n* (%)                                                 125 (59.2)                                          125 (60.1)       120 (57.1)       117 (55.7)
  Coronary heart disease, *n* (%)                                       41 (19.4)                                           39 (18.8)        37 (17.6)        39 (18.6)
  Diabetes mellitus, *n* (%)                                            34 (16.1)                                           30 (14.4)        26 (12.4)        23 (11.0)
  Obesity (BMI ≥30 kg/m^2^), *n* (%)                                    59 (28.0)                                           55 (26.4)        49 (23.3)        49 (23.3)

*n* = 839. Quartile distribution of anthocyanin intake was derived from intake estimated at first visit; the median (IQR) for year of first visit was 1994 (1993, 1996). FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity.

Unadjusted mean ± SD (all such values).

Excluding 160 participants with a first visit in 1992 when estimation of total fiber intake was not available; numbers of participants in quartiles 1, 2, 3, and 4 are 173, 164, 167, and 175, respectively.

Includes EPA and DHA, no α-linolenic acid.

After multivariate adjustment for a range of lifestyle and dietary factors, higher total anthocyanin intake significantly (*P* \< 0.05) attenuated the rates of age-related annual decline in FEV~1~ and FVC ([**Figures 1**](#fig1){ref-type="fig"} and [**2**](#fig2){ref-type="fig"}, respectively). Compared with participants in the first quartile, participants in the fourth quartile of anthocyanin intake had a slower rate of FEV~1~ decline by 23.6 (95% CI, 16.6, 30.7) mL/y ([Figure 1](#fig1){ref-type="fig"}, [**Table 2**](#tbl2){ref-type="table"}). The linear trend for adjusted difference in annual change in FEV~1~ across quartiles of increasing anthocyanin intake was also significant (*P*-trend \< 0.0001). A similar pattern of association was also observed for FVC as shown in [Figure 2](#fig2){ref-type="fig"}. Compared with participants in the first quartile, participants in the fourth quartile of anthocyanin intake had a slower rate of decline in FVC by 37.3 (95% CI: 27.8, 46.8) mL/y (*P*-trend \< 0.0001) ([Figure 2](#fig2){ref-type="fig"}, [**Table 3**](#tbl3){ref-type="table"}). There was little difference in the observed associations for anthocyanin intake between the minimal and fully adjusted models ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}, respectively). Furthermore, the observed associations between anthocyanin intake and annual change in FEV~1~ and FVC were robust after the application of stabilized inverse probability weights.

![Adjusted mean (95% CI) annual decline in FEV~1~ by quartile of total anthocyanin intake. The annual FEV~1~ decline for each quartile of anthocyanin intake was estimated in a linear mixed regression model of FEV~1~ with a random intercept for study participant and adjusting for the following covariates: time since first visit, age at first visit, height, race, presence of obstructive lung diseases, asthma medication use, statin medication use, education, percentage of census tract below poverty level, smoking status, pack-years of smoking, physical activity, total energy intake, total fruit intake, total vegetable intake, and 2-way interaction terms between time since first visit and each quartile of anthocyanin intake; the variable coefficient for time since first visit reflects the adjusted mean annual FEV~1~ decline for quartile of anthocyanin intake that is assigned the reference category. ^1^The *P* value for test of linear trend across quartile categories of anthocyanin intake was based on a linear mixed regression model in which the value of median intake was assigned to each category of anthocyanin intake; this quartile median variable was used as a continuous measure in the regression model. ^2^*P* values for quartiles 2, 3, and 4 are for the *F* test comparison with quartile 1. ^3^Median values are presented for each quartile category of anthocyanin intake. FEV~1~, forced expiratory volume in 1 s.](ajcn121467fig1){#fig1}

![Adjusted mean (95% CI) annual decline in FVC by quartile of total anthocyanin intake. The annual FVC decline for each quartile of anthocyanin intake was estimated in a linear mixed regression model of FVC with a random intercept for study participant and adjusting for the following covariates: time since first visit, age at first visit, height, race, presence of obstructive lung diseases, asthma medication use, statin medication use, education, percentage of census tract below poverty level, smoking status, pack-years of smoking, physical activity, total energy intake, total fruit intake, total vegetable intake, and 2-way interaction terms between time since first visit and each quartile of anthocyanin intake; the variable coefficient for time since first visit reflects the adjusted mean annual FVC decline for quartile of anthocyanin intake that is assigned the reference category. ^1^The *P* value for test of linear trend across quartile categories of anthocyanin intake was based on a linear mixed regression model in which the value of median intake was assigned to each category of anthocyanin intake; this quartile median variable was used as a continuous measure in the regression model. ^2^*P* values for quartiles 2, 3, and 4 are for the *F* test comparison with quartile 1. ^3^Median values are presented for each quartile category of anthocyanin intake. FVC, forced vital capacity.](ajcn121467fig2){#fig2}

###### 

Adjusted differences in annual changes in FEV~1~ (mL/y) for yearly average anthocyanin, flavan-3-ol, and polymer subclass intakes[^1^](#tblfn5){ref-type="table-fn"}

                                                                 Adjusted mean annual change in FEV~1~            Adjusted difference in mean annual change in FEV~1~ relative to quartile 1                                           
  -------------------------------------------------------------- ------------------------------------------------ ---------------------------------------------------------------------------- ------------------ -------------------- ----------
  Anthocyanins                                                                                                                                                                                                                         
   Median intake, mg/d                                           1.3                                              4.4                                                                          13.6               25.3                 ---
   Person-visits, *n*                                            657                                              654                                                                          656                656                  ---
   Minimally adjusted model[^3^](#tblfn7){ref-type="table-fn"}   −51.4 ± 2.7[^4^](#tblfn8){ref-type="table-fn"}   7.6 (0.2, 15.2)[^5^](#tblfn9){ref-type="table-fn"}                           12.3 (5.2, 19.5)   22.8 (15.8, 29.78)   \<0.0001
   Fully adjusted model[^6^](#tblfn10){ref-type="table-fn"}      −51.7 ± 2.8                                      7.8 (0.3, 15.2)                                                              13.0 (5.8, 20.2)   23.6 (16.6, 30.7)    \<0.0001
   IPW model[^7^](#tblfn11){ref-type="table-fn"}                 −52.0 ± 2.8                                      6.8 (−0.6, 13.7)                                                             13.7 (6.6, 20.9)   22.9 (15.9, 29.9)    \<0.0001
  Flavan-3-ols                                                                                                                                                                                                                         
   Median intake, mg/d                                           9.7                                              21.4                                                                         45.7               99.3                 ---
   Person-visits,*n*                                             656                                              655                                                                          656                656                  ---
   Minimally adjusted model[^3^](#tblfn7){ref-type="table-fn"}   −41.1 ± 2.5                                      2.1 (−4.9, 9.0)                                                              2.0 (−4.9, 9.0)    6.2 (−0.5, 12.9)     0.07
   Fully adjusted model[^6^](#tblfn10){ref-type="table-fn"}      −41.2 ± 2.6                                      1.9 (−5.1, 8.9)                                                              2.7 (−4.3, 9.6)    6.6 (−0.1, 13.3)     0.05
   IPW model[^7^](#tblfn11){ref-type="table-fn"}                 −42.2 ± 2.6                                      0.9 (−6.2, 7.9)                                                              4.7 (−2.2, 11.6)   7.1 (0.4, 13.9)      0.02
  Polymers                                                                                                                                                                                                                             
   Median intake, mg/d                                           46.6                                             109.3                                                                        201.6              440.6                ---
   Person-visits, *n*                                            656                                              655                                                                          656                656                  ---
   Minimally adjusted model[^3^](#tblfn7){ref-type="table-fn"}   −41.2 ± 2.6                                      0.3 (−6.8, 7.4)                                                              4.0 (−3.1, 11.1)   5.8 (−1.1, 12.6)     0.08
   Fully adjusted model[^6^](#tblfn10){ref-type="table-fn"}      −41.3 ± 2.7                                      0.6 (−6.6, 7.7)                                                              4.4 (−2.8, 11.5)   6.1 (−0.8, 13.0)     0.07
   IPW model[^7^](#tblfn11){ref-type="table-fn"}                 −42.3 ± 2.7                                      0.8 (−6.4, 8.0)                                                              5.4 (−1.7, 12.5)   6.7 (−0.2, 13.6)     0.05

FEV~1~, forced expiratory volume in 1 s; IPW, inverse probability weight.

*P* values for the test of linear trend across quartile categories of flavonoid subclass intake were based on a linear mixed regression model with the value of median intake assigned to each quartile category of flavonoid subclass intake; this quartile median variable was used as a continuous measure in the regression model.

As estimated in linear mixed-effects regression model of FEV~1~ with a random intercept for study participant and adjusting for the following covariates: flavonoid intake (mg/d, in quartiles), time since first visit (y), age at first visit (y), height (cm), and total energy intake (kcal/d, in quartiles); β is the variable coefficient for the interaction between time since first visit and category of flavonoid subclass intake where quartile 1 is the reference category.

Mean ± SEM (all such values).

β 95% CI in parentheses (all such values).

The fully adjusted model includes additional adjustment for race (black or white as reference), smoking status (current smoker, recent quitter, longtime quitter, or never smoker as reference), cumulative pack-years smoked, physician diagnosis of chronic bronchitis or asthma or emphysema (no as reference), asthma medication use (no as reference), statin medication use (no as reference), years of education (\<12, 12, 13--15, \>15 y as reference), percentage of census tract below poverty level, total fruit intake (servings/d, in quartiles), total vegetable intake (servings/d, in quartiles), and physical activity (metabolic equivalent tasks/wk, in quartiles).

The IPW model is the fully adjusted model after application of stabilized inverse weights for censoring by loss to follow-up.

###### 

Adjusted differences in annual change in FVC (mL/y) yearly average anthocyanin, flavan-3-ol, and polymer subclass intakes[^1^](#tblfn12){ref-type="table-fn"}

                                                                                                                    Adjusted difference in mean annual change in FVC relative to quartile 1                                           
  --------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------------------- ------------------- ------------------- ----------
  Anthocyanins                                                                                                                                                                                                                        
   Median intake, mg/d                                            1.3                                               4.4                                                                       13.6                25.3                
   Person-visits, *n*                                             657                                               654                                                                       656                 656                 
   Minimally adjusted model[^3^](#tblfn14){ref-type="table-fn"}   −69.5 ± 3.7[^4^](#tblfn15){ref-type="table-fn"}   13.7 (3.7, 23.8)[^5^](#tblfn16){ref-type="table-fn"}                      18.7 (9.0, 28.4)    36.5 (27.0, 45.9)   \<0.0001
   Fully adjusted model[^6^](#tblfn17){ref-type="table-fn"}       −68.9 ± 3.8                                       13.7 (3.6, 23.7)                                                          19.2 (9.5, 28.9)    37.3 (27.8, 46.8)   \<0.0001
   IPW model[^7^](#tblfn18){ref-type="table-fn"}                  −68.4 ± 3.7                                       11.2 (1.2, 21.2)                                                          19.2 (9.6, 28.8)    35.6 (26.2, 45.0)   \<0.0001
  Flavan-3-ols                                                                                                                                                                                                                        
   Median intake, mg/d                                            9.7                                               21.4                                                                      45.7                99.3                
   Person-visits, *n*                                             656                                               655                                                                       656                 656                 
   Minimally adjusted model[^3^](#tblfn14){ref-type="table-fn"}   −51.3 ± 3.3                                       3.2 (−6.3, 12.7)                                                          −2.4 (−11.8, 7.1)   8.4 (−0.8, 17.5)    0.09
   Fully adjusted model[^6^](#tblfn17){ref-type="table-fn"}       −50.3 ± 3.5                                       2.4 (−7.0, 11.9)                                                          −2.0 (−11.4, 7.4)   8.6 (−0.5, 17.8)    0.06
   IPW model[^7^](#tblfn18){ref-type="table-fn"}                  −51.4 ± 3.5                                       0.6 (−8.9, 10.0)                                                          1.2 (−8.2, 10.5)    9.5 (0.4, 18.5)     0.02
  Polymers                                                                                                                                                                                                                            
   Median intake, mg/d                                            46.6                                              109.3                                                                     201.6               440.6               
   Person-visits, *n*                                             656                                               655                                                                       656                 656                 
   Minimally adjusted model[^3^](#tblfn14){ref-type="table-fn"}   −52.4 ± 3.5                                       0.7 (−8.9, 10.4)                                                          3.8 (−5.8, 13.5)    8.5 (−0.8, 17.8)    0.05
   Fully adjusted model[^6^](#tblfn17){ref-type="table-fn"}       −51.3 ± 3.7                                       0.5 (−9.2, 10.1)                                                          3.9 (−5.7, 13.6)    8.4 (−0.9, 17.7)    0.05
   IPW model[^7^](#tblfn18){ref-type="table-fn"}                  −52.8 ± 3.7                                       0.7 (−9.1, 10.4)                                                          6.3 (−3.4, 15.9)    9.5 (0.2, 18.8)     0.03

FVC, forced vital capacity; IPW, inverse probability weight.

*P* values for the test of linear trend across quartile categories of flavonoid subclass intake were based on a linear mixed regression model with the value of median intake assigned to each quartile category flavonoid subclass intake; this quartile median variable was used as a continuous measure in the regression model.

As estimated in linear mixed-effects regression model of FVC with a random intercept for study participant and adjusting for the following covariates: flavonoid intake (mg/d, in quartiles), time since first visit (y), age at first visit (y), height (cm), and total energy intake (kcal/d, in quartiles); β is the variable coefficient for the interaction between time since first visit and category of flavonoid subclass intake where quartile 1 is the reference category.

Mean ± SEM (all such values).

β 95% CI in parentheses (all such values).

The fully adjusted model includes additional adjustment for race (black, white as reference), smoking status (current smoker, recent quitter, longtime quitter, or never smoker as reference), cumulative pack-years smoked, physician diagnosis of chronic bronchitis or asthma or emphysema (no as reference), asthma medication use (no as reference), statin medication use (no as reference), years of education (\<12, 12, 13--15, \>15 y as reference), percentage of census tract below poverty level, total fruit intake (servings/d, in quartiles), total vegetable intake (servings/d, in quartiles), and physical activity (metabolic equivalent tasks/wk, in quartiles).

The IPW model is the fully adjusted model after application of stabilized inverse weights for censoring by loss to follow-up.

To a lesser extent, an attenuation of lung function decline was also observed for intake of flavan-3-ols and polymers in the highest quartile. After application of stabilized inverse probability weights, participants in the fourth quartile of flavan-3-ol intake had a significantly slower rate of decline in FEV~1~ and FVC by 7.1 (95% CI: 0.4, 13.9) and 9.5 (95% CI: 0.4, 18.5) mL/y, respectively (*P*-trend = 0.02) compared with participants in the lowest quartile ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}, respectively). A positive association of similar magnitude was observed for polymer intake in the fourth quartile and annual change in FVC (*P*-trend = 0.03) ([Table 3](#tbl3){ref-type="table"}).

The results for the other flavonoid subclasses are presented in the **Supplemental Tables 2**and**3**. No significant associations were observed for flavonol and flavone subclasses. Significant negative associations were observed between the second and fourth quartiles of flavonone intake and annual change in FVC, indicating faster decline in FVC in association with flavonone intake (Supplemental Table 3); in contrast, a positive association of similar magnitude was observed for flavonone intake in the second quartile and a linear trend was not observed. However, the observed changes in FVC for the second and fourth quartiles of flavonone intake were reduced moderately after the application of stabilized inverse probability weights and were nonsignificant.

After stratification by smoking status, slower rates of annual decline in FEV~1~ and FVC in association with total anthocyanin intake were observed in both current/former smokers and in never smokers (**Supplemental Table 4**). Although the slowest rates of decline in association with anthocyanin intake were found in never smokers, a 3-way interaction between smoking status, anthocyanin intake, and time since first visit on lung function was not significant. Similarly, no interactions were observed between anthocyanin intake and the presence of obstructive lung diseases and obesity (data not shown). The adjusted differences in annual lung function decline for anthocyanin intake remained robust after additional individual adjustment for intakes of total dietary fiber, hot or cold breakfast cereal, vitamin C, caffeine, n--3 fatty acids, fish, and processed meats and for the presence of comorbid conditions including hypertension, coronary heart disease, and diabetes mellitus (**Supplemental Tables 5**and**6**).

The results of food-based analyses utilizing all FFQs collected between 1992 and 2004 indicate that intakes of blueberries (49.9%), red wine (17.6%), and strawberries (15.5%) contributed most to overall anthocyanin intake. To confirm our findings for total anthocyanin intake and to relate the effects on lung function decline to public health and dietary guidelines, we examined associations between weekly intakes of blueberries, red wine, and strawberries and annual change in lung function. Blueberry intake was associated with the slowest rate of annual decline in lung function; compared with no or very low intake, consuming ≥2 servings of blueberries/wk was associated with a slower rate of decline in FEV~1~ and FVC by 22.5 (95% CI: 10.5, 34.2) and 37.6 (95% CI: 21.8, 53.4) mL/y, respectively (*P*-trend \< 0.0001) ([**Table 4**](#tbl4){ref-type="table"}). To a lesser extent, similar findings were observed for strawberry intake. No significant associations were observed for red wine intake (data not shown).

###### 

Adjusted differences in mean annual change in lung function (mL/y) for blueberry and strawberry intakes[^1^](#tblfn19){ref-type="table-fn"}

                        Mean annual change                                Adjusted difference in mean annual change                                                    
  --------------------- ------------------------------------------------- ----------------------------------------------------- ------------------ ------------------- ----------
  Blueberries                                                                                                                                                          
   Person-visits, *n*   1596                                              723                                                   196                108                 
   FEV~1~               −41.5 ± 1.7[^3^](#tblfn21){ref-type="table-fn"}   2.9 (−2.7, 8.4)[^4^](#tblfn22){ref-type="table-fn"}   17.0 (7.7, 26.3)   22.5 (10.8, 34.2)   \<0.0001
   FVC                  −53.1 ± 2.3                                       7.0 (−0.5, 14.5)                                      18.5 (6.0, 31.1)   37.9 (22.1, 53.7)   \<0.0001
  Strawberries                                                                                                                                                         
   Person-visits, *n*   1188                                              963                                                   304                168                 
   FEV~1~               −42.8 ± 2.0                                       4.8 (−0.6, 10.3)                                      14.5 (6.6, 22.5)   13.1 (3.8, 22.4)    \<0.0001
   FVC                  −51.4 ± 2.7                                       7.7 (0.3, 15.1)                                       16.1 (5.3, 26.1)   19.7 (7.0, 32.3)    \<0.0001

As estimated in linear mixed regression models of FEV~1~ (and FVC) with a random intercept for study participant and adjusting for the following covariates: time since first visit, age at first visit, height, race, smoking status, cumulative pack-years smoked, physician diagnosis of chronic bronchitis or asthma or emphysema, asthma medication use, statin use, years of education, percentage of census tract below poverty level, total energy intake, total fruit intake, total vegetable intake, and physical activity. β is the variable coefficient for the interaction between time since first visit and category of blueberry and strawberry intake where no intake or \<1 serving/mo is the reference category. FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity.

*P* values for the test of linear trend across categories of blueberry (and strawberry) intake were based on a linear mixed regression model where the ordinal variable for blueberry (and strawberry) intake was used as a continuous measure.

Mean ± SEM (all such values).

β 95% CI in parentheses (all such values).

DISCUSSION
==========

Our findings suggest that habitual anthocyanin intake was associated with slower age-related decline in FEV~1~ and FVC, independent of established dietary and nondietary risk factors. In addition, an attenuation of lung function decline associated with anthocyanin intake was stronger in never smokers than in ever smokers. To a lesser extent, an attenuation of lung function decline was also observed for intakes of flavan-3-ols and polymers in the highest quartile. The beneficial changes in lung function over time associated with anthocyanin intake complement findings from recent studies that suggest protective effects of these compounds on a number of chronic diseases including cardiovascular disease and associated risk factors ([@b22]--[@b24], [@b41]).

Anthocyanins are present in red/blue fruits and may, in part, explain the previously reported population-based evidence that showed that fruit consumption was positively related to lung function and protective against the incidence of chronic nonspecific lung diseases ([@b7], [@b42], [@b43]). In food-based analyses of the main anthocyanin sources, an attenuation of lung function decline was also observed for frequent intakes of blueberries and strawberries. The beneficial changes in lung function associated with frequent consumption of berries may possibly exceed the decline in lung function attributable to smoking, assuming that moderate- to-heavy smoking men have, on average, a 15-mL/y larger decline in FEV~1~ than do nonsmokers ([@b44]). The beneficial change in FEV~1~ associated with the highest quartile of anthocyanin intake is within the range of a previously reported association between vitamin C intake and reduction in decline in FEV~1~ (50.8 mL/y; 95% CI: 3.8, 97.9 mL/y) from a general population--based study in the United Kingdom ([@b8]).

The present study provides novel evidence that suggests that berries may contain specific constituents that may attenuate lung function decline. The addition of total dietary fiber, vitamin C, and other dietary constituents, including total fruit and total vegetable intake, to our multivariate model did not substantially influence the observed associations between anthocyanin intake and longitudinal change in lung function. These findings suggest that the benefits of anthocyanins are specific and not simply reflective of those who eat a high-plant-based diet.

A growing body of evidence from experimental studies supports a role for anthocyanins and their degradation products/microbial metabolites on mechanisms involved in lung function. The microbiome is likely to play a key role in the bioactivity of anthocyanins because degradation is swift after intake and the microbially derived metabolites are present in the circulation longer and at higher concentrations than the parent anthocyanins ([@b45]--[@b48]). Recent findings from in vitro studies suggest that nutritionally relevant amounts of these downstream metabolites exert a greater anti-inflammatory effect than the parent molecules ([@b49], [@b50]), although the impact on airway inflammation is unknown. Previous studies also showed that anthocyanins, including anthocyanin-rich bilberry extract, can inhibit the activation of nuclear transcription factor κB ([@b51]--[@b53]) and attenuate oxidative stress through activations of the Nuclear factor, erythroid 2-like 2 (Nrf2) signaling pathway ([@b54]). In a recent cross-sectional analysis in 2375 Framingham Heart Study Offspring Cohort participants, habitual intakes of both total anthocyanins and strawberries were inversely associated with a combined inflammatory score, which integrated a range of inflammatory and oxidative stress biomarkers ([@b24]). In the limited experimental human studies conducted to date, berry intake was also associated with improved markers of oxidative stress including cell antioxidant defense against DNA damage ([@b28], [@b29], [@b55], [@b56]).

Only 2 previous observational studies ([@b20], [@b21]) examined associations between flavonoid intake and lung function. These studies used earlier flavonoid databases that covered only a few subclasses and did not include anthocyanins or flavanones. When combining the intakes of flavan-3-ol, flavonol, and flavone subclasses, a 44-mL higher difference in FEV~1~ level was observed when comparing extreme intake quintiles (117 compared with 15 mg/d) in a large cross-sectional analysis in 13,651 adults in the Netherlands ([@b20]). Similarly, investigators in Chile observed 100- and 70-mL differences in FVC level when comparing highest to lowest quintiles of flavonol and flavan-3-ol intakes, respectively, in a cross-sectional analysis in 1232 young adults ([@b21]). Although we hypothesized that higher intakes of flavones, flavonols, flavan-3-ols, and their polymeric forms would also attenuate lung function decline over time, no associations were observed for flavone and flavonol intake in the present study. However, a slower decline in FEV~1~ and FVC over time was also observed with a high intake of flavan-3-ols. A similar finding was also observed for a high intake of polymers and FVC decline.

The strengths of this study include the longitudinal design with multiple repeat measures of dietary flavonoid intake and lung function to evaluate longitudinal change, a large sample size with long-term follow-up, adjustment for multiple confounders, and methods to address selection bias. Our databases also allowed us to comprehensively assess the range of flavonoids present in the habitual diet. However, there are a number of limitations to consider. Our findings relate to predominantly elderly white men; thus, the generalizability to women and younger and other racial-ethnic population groups requires further study. Although we adjusted for possible confounders that are known to be associated with lung function, there remains the possibility of residual confounding with respect to these factors or unmeasured confounding from additional unmeasured factors. However, given our detailed and updated adjustment for potential confounders, it is unlikely that these would account fully for the associations we observed.

Average daily flavonoid subclass intakes were calculated from a database developed by using recent USDA databases with additional input from European Union sources (EuroFIR eBASIS; <http://www.eurofir.org>), allowing us to robustly assess intakes using the best available databases at the time. Flavonoid content also varies depending on a number of factors, including growing conditions, processing, and storage; however, despite these variations, these data allowed us to rank participants and compare low and high intakes in large population groups. Although our FFQ has not been specifically validated for intakes of flavonoid subclasses, correlations between the main dietary sources of flavonoids (fruit, tea, vegetables, and wine) have been determined for our FFQ ([@b57], [@b58]) and flavonoid biomarkers are correlated with intakes of fruit and vegetables ([@b59]). Current research is moving closer to identifying biomarkers of anthocyanin intake ([@b46]), but it is possible that our findings for anthocyanins might be due to other constituents found in the foods that contribute most to this subclass. However, even additional adjustment of other potentially beneficial constituents of fruit, including vitamin C and fiber, did not substantially attenuate the relation between anthocyanins and lung function, suggesting that anthocyanins may be another important dietary constituent. In an observational cohort study such as the VA Normative Aging Study, it is impossible to disentangle the relative influence of all of the constituents of plant-based foods.

In summary, we observed that a higher dietary intake of anthocyanins was associated with an attenuation of lung function decline in this longitudinal sample of predominantly elderly white men. The present findings suggest a potential role for anthocyanins in berry fruit in slowing age-related decline in lung function. Further prospective studies are needed to confirm these novel associations.
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